Stereotaxis submits EMAGIN 5F catheter to FDA, expanding robotic navigation into stroke, cancer, and cardiovascular treatments with European submission following.

Surgical robotics pioneer Stereotaxis gains NVIDIA's backing for AI integration. With 150,000+ treatments completed, this partnership accelerates next-gen medical robotics development.

Deborah Heart and Lung Center pioneers first US use of Stereotaxis’ MAGiC Sweep catheter for robotic arrhythmia mapping.

MAGiC Sweep offers 20-electrode mapping, enhanced safety, and improved access to difficult cardiac regions, with commercial launch expected in H2 2025.

Hungary's first robotic cardiology programme treated over 70 arrhythmia patients in its opening month, a record pace for Stereotaxis's Genesis system.

Reported Thursday, Aug 27 - 5:50am EDT (TheFly subscription required to read more.)

Stereotaxis (NYSE: STXS) reported 2026 second quarter revenue of $7.7 million, down from $8.8 million a year earlier, with systems revenue at $1.5 million and recurring revenue at $6.2 million. Robotic catheter revenue surpassed $1 million, growing 270% sequentially, supported by initial Synchrony digital operating room sales following FDA clearance in April.Gross margin was 58%, including 66% on recurring revenue and 29% on systems. Operating expenses were $9.1 million, including $2.5 million of non-cash charges, resulting in a net loss of $4.5 million. Negative free cash flow was $3.7 million. At June 30, 2026, the company held $10.5 million in cash and had no debt. Stereotaxis completed its previously announced acquisition of Robocath and reported the first U.S. purchase of a GenesisX robotic system, expected to be installed this fall.

Reported Tuesday, Aug 11 - 4:04pm EDT (TheFly subscription required to read more.)

Click to view the official SEC document.

Stereotaxis (NYSE: STXS) announced that the University of Szeged has launched Hungary’s first advanced robotic cardiology program using the Genesis Robotic Magnetic Navigation System at its Cardiology Center. The hospital is the first in the country to establish a heart rhythm program based on this technology and has already successfully treated its first patients across a broad range of cardiac arrhythmias.According to Stereotaxis and University leadership, Genesis is intended to improve the precision and safety of catheter ablation therapy, with expectations to treat hundreds of arrhythmia patients annually, serve as a central training institute, and support pioneering research in robotic cardiology.

Click to view the official SEC document.

Reported Wednesday, Jul 15 - 5:27pm EDT (TheFly subscription required to read more.)

Reported Wednesday, Jul 15 - 5:23pm EDT (TheFly subscription required to read more.)

Stereotaxis cleared by FDA on Apr 6, 2026; STXS stock moved up ~8% intraday. Synchrony targets the U.S. ablation market with ~100k–150k annual AF procedures.

Stereotaxis receives FDA approval for MAGiC catheter, a magnetically-guided robotic device for treating complex heart rhythm disorders in hard-to-reach patients.